TAKEDA PHARMACEUTICAL TO ACQUIRE RIGHTS TO DEVELOP AND COMMERCIALIZE DPP4 INHIBITOR

Takeda Pharmaceutical (TSE: 4502) announced on July 14 that it has agreed with Pharmaceutical Product Development (PPD), a US pharmaceutical company, concerning rights to the dipeptidyl peptidase IV (DPP4) inhibitor. Under the terms of the agreement, Takeda will be licensed to develop and commercialize the DPP inhibitor. The company will make an upfront payment of $15 million as well as development-based milestone and sales royalty payments.

JCN Network (http://japancorp.net/Article.Asp?Art_ID=10503)